This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Class Action Against Blyth, Inc. (BTH), Zillow, Inc. (Z) And SinoHub, Inc. (SIHI) And Investigation Of Peregrine Pharmaceuticals, Inc. (PPHM)

NEW YORK, Dec. 19, 2012 /PRNewswire/ --

Blyth, Inc.

Levi & Korsinsky announces that a class action lawsuit has been commenced in the USDC for the District of Connecticut on behalf of investors who purchased Blyth, Inc. (NYSE: BTH) stock between March 14, 2012 and November 6, 2012.

(Logo:  http://photos.prnewswire.com/prnh/20120409/MM84375LOGO)

For more information, click here: http://zlk.9nl.com/blyth-bth .  You have until January 12, 2013 to request that the Court appoint you as lead plaintiff.

Zillow, Inc.

Levi & Korsinsky announces that a class action lawsuit has been commenced in the USDC for the Western District of Washington on behalf of investors who acquired Zillow, Inc. (Nasdaq: Z) stock between February 15, 2012 and November 6, 2012.

For more information, click here: http://zlk.9nl.com/zillow-z/ You have until January 28, 2013 to request that the Court appoint you as lead plaintiff.

SinoHub, Inc.

Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased SinoHub, Inc. (OTC: SIHI) stock between May 17, 2010 and August 21, 2012.

For more information, click here: http://zlk.9nl.com/sinohub-sihi/ .  You have until January 21, 2013 to request that the Court appoint you as lead plaintiff.

Peregrine Pharmaceuticals, Inc.

Levi & Korsinsky is investigating potential claims on behalf of purchasers of Peregrine Pharmaceuticals, Inc. (NasdaqCM: PPHM) securities concerning possible breaches of fiduciary duty in connection with the disclosure of the discovery of major discrepancies in the treatment group of its Bavituxmab Phase II Second-Line Non-Small Cell Lung Cancer Trial.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,598.20 -91.66 -0.52%
S&P 500 2,098.04 -5.80 -0.28%
NASDAQ 5,115.3820 -12.8990 -0.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs